Related by context. All words. (Click for frequent words.) 67 antiangiogenic therapy 64 clinically meaningful improvement 64 K ras mutations 64 TNF antagonist 64 prostate cancer CaP 63 virological response 63 viral kinetics 63 interferon therapy 63 myocardial necrosis 62 Doxil ® 62 paraprotein 62 serum antibody 62 dopaminergic therapy 62 mg kg dose 62 AST ALT 62 HER2 expression 62 androgen ablation 62 tumorigenicity 61 EBV infection 61 mTOR inhibitors 61 pegylated interferon ribavirin 61 pCR 61 imatinib therapy 61 relapsed AML 61 antitumor effect 61 dose cohort 61 androgen deprivation 61 taxane therapy 61 bezafibrate 61 PSA nadir 60 AGHD 60 splenectomized patients 60 riociguat 60 MGd 60 glomerular filtration 60 prognostic indicators 60 adrenal suppression 60 infliximab therapy 60 thyroid carcinoma 60 haematologic 60 urate levels 60 antibody titer 60 thrombotic complications 60 HER2 amplification 60 methotrexate monotherapy 60 isoproterenol 60 IFN γ 60 lymphocytosis 60 serum urate 60 Febrile neutropenia 60 IL 1ß 60 airway narrowing 60 nephrotoxicity 60 perioperatively 59 pomalidomide 59 virologic response 59 prolonged QT interval 59 curative resection 59 corticosteroid therapy 59 vivo potency 59 severe neutropenia 59 achieved sustained virological 59 neurodevelopmental outcome 59 hepatic enzyme 59 galiximab 59 lenalidomide dexamethasone 59 oncologic outcomes 59 alteplase 59 concomitant medications 59 adriamycin 59 recurrent VTE 59 trastuzumab Herceptin ® 59 APTIVUS r 59 hematologic parameters 59 leukemia AML 59 lymphoma subtypes 59 mutated KRAS 59 invasive candidiasis 59 angiographically 59 adrenalectomy 59 hypercalcemia 59 virological failure 59 Leydig cell 59 MYLOTARG 59 β blockers 59 crizotinib PF # 59 thromboembolic complications 59 serum urate levels 59 serum HCV RNA 59 interferon γ 59 anthracycline chemotherapy 59 flutamide 59 cytogenetic abnormalities 59 relapsed MM 59 BRAF mutations 59 mapatumumab 59 thiopurine 59 intracerebral haemorrhage 59 virologic responses 59 urine cytology 59 alkylating agent 59 cytopenias 59 virologic 59 cisplatin chemotherapy 59 S. maltophilia 59 antioxidant supplementation 59 caspofungin 59 viral titers 58 adjuvant tamoxifen 58 aminotransferase levels 58 asthma exacerbation 58 Subgroup analysis 58 hemodynamic variables 58 Gleevec resistant 58 NATRECOR ® 58 airway hyperresponsiveness 58 decitabine 58 mTOR inhibition 58 timepoints 58 interferon ribavirin 58 hepatorenal syndrome 58 EXJADE 58 liver metastasis 58 Vectibix monotherapy 58 molecular remissions 58 neutralizing antibody 58 chemosensitivity 58 HBeAg seroconversion 58 FDG PET imaging 58 serum BDNF 58 HIV HCV coinfected 58 azacytidine 58 tipranavir ritonavir 58 VAPRISOL 58 Tarceva TM 58 lactate dehydrogenase 58 Subgroup analyzes 58 refractory prostate cancer 58 durable remissions 58 complete cytogenetic 58 Th2 immune 58 rFVIIa 58 prognostic significance 58 idarubicin 58 NNRTI resistance 58 posttransplant 58 systolic dysfunction 58 intracoronary 58 Virological 58 cardiac repolarization 58 docetaxel chemotherapy 58 QT QTc 58 refractory CLL 58 relapsed ovarian cancer 58 histological subtype 58 fluvastatin 58 imatinib Gleevec 58 posaconazole 58 methacholine 58 olmesartan 58 surgical debulking 58 chlorambucil 58 dasatinib 58 posttreatment 58 taxane chemotherapy 58 platelet reactivity 58 tumor histology 58 oblimersen 58 CRp 58 thyrotropin 58 Zevalin consolidation 58 histologic subtype 58 monoinfected patients 58 intravenous cyclophosphamide 58 chemoradiotherapy 58 tipranavir r 58 colorectal adenoma 58 recurrent glioblastoma multiforme 58 antibody mediated 58 rebleeding 58 coronary stenosis 58 chest radiographs 58 pamidronate 58 hematopoietic cancers 58 premenopause 58 p = #.# [003] 58 tumor regressions 58 radiographic progression 58 antibody titers 58 radiochemotherapy 58 electrophysiologic 58 acoustic startle 58 prognostic variables 58 MetMAb 58 ispinesib administered 58 KRAS mutations occur 58 CLL SLL 58 epithelial ovarian cancer 58 PASI scores 58 cranial irradiation 57 complete cytogenetic response 57 mRCC 57 pegylated alpha interferon 57 aminotransferases 57 hyperacute 57 HSCT 57 NAbs 57 gefitinib Iressa 57 chlamydial infection 57 coronary stenoses 57 postoperative chemotherapy 57 bortezomib Velcade 57 transaminase levels 57 hepatic enzymes 57 F FDG PET 57 biochemical abnormalities 57 KRAS mutation 57 plus dexamethasone 57 nonresponders 57 concomitant antibiotics 57 aromatase inhibitor therapy 57 HER2 overexpression 57 androgen suppression 57 neurocognitive deficits 57 hematologic toxicity 57 neovascular 57 APOPTONE 57 adalimumab etanercept 57 pharmacodynamic PD 57 bleomycin 57 octreotide LAR 57 postoperative complication 57 CHOP chemotherapy 57 hyperalgesia 57 IFN α 57 tumor necrosis 57 myeloablative 57 elevated IOP 57 pDCs 57 hepatic fibrosis 57 resynchronization therapy 57 bronchial hyperresponsiveness 57 levodopa therapy 57 EGFR mutation status 57 allogeneic HSCT 57 metastatic malignant 57 ACTEMRA TM 57 hepatic toxicity 57 plasma pharmacokinetics 57 QT intervals 57 biochemical recurrence 57 PCa 57 CP CPPS 57 renal cysts 57 virologic failure 57 leukocytosis 57 ACZ# 57 lupus nephritis 57 FluCAM 57 Tumor shrinkage 57 parkinsonian symptoms 57 recurrent GBM 57 alanine aminotransferase ALT 57 hypoperfusion 57 hsCRP levels 57 intratumoral 57 intermittent dosing 57 spirometric 57 ELACYT 57 breast carcinoma 57 carcinoids 57 serum lipid 57 complete remissions 57 etiologic 57 CR nPR 57 Clusterin 57 recurrent venous thromboembolism 57 previously untreated follicular 57 intact parathyroid hormone 57 thyrotoxicosis 57 sustained virologic response 57 CCyR 57 nonobstructive CAD 57 periprocedural 57 leukocyte count 57 refractory acute myeloid 57 HBeAg 57 BCR ABL mutations 57 glycated hemoglobin levels 57 nadolol 57 albumin excretion 57 Natalizumab 57 imatinib 57 DAS# CRP 57 alkaline phosphatase ALP 57 seminomas 57 EGFR TKIs 57 fibrinolysis 57 transgene expression 57 LHRH agonists 57 acute GvHD 57 serum biomarkers 57 TMPRSS2 ERG 57 moderately emetogenic 57 TNF inhibitor therapy 57 clomipramine 57 postintervention 57 Dose escalation 57 progression TTP 57 neurocognitive function 57 goserelin 57 fulvestrant 57 ribavirin therapy 57 CR CRu 57 acromegalic patients 57 hypoglycemic episodes 57 lumiliximab 57 follicular lymphoma FL 57 gemifloxacin 57 TTR gene 57 SRBD 57 malignant pleural mesothelioma 56 CIMZIA ™ 56 ANAVEX #-# [001] 56 anti angiogenic agents 56 nonmetastatic prostate cancer 56 CIN3 56 chronicity 56 LV dysfunction 56 postoperative AF 56 thalidomide Thalomid 56 Chronic pancreatitis 56 CsA 56 mCRC patients 56 invasive aspergillosis 56 D dimer 56 symptomatic VTE 56 renal scarring 56 lactate dehydrogenase LDH 56 heavily pretreated 56 azacitidine 56 chronic lymphocytic leukemia CLL 56 plasma renin activity 56 NMIBC 56 NIH CPSI 56 p# activation 56 H. pylori eradication 56 PROCHYMAL 56 antiarrhythmic drugs 56 cortical activation 56 antiviral efficacy 56 PhG alpha 1 56 antigen PSA levels 56 beta blocker therapy 56 canakinumab 56 neutrophil count 56 plasma uric acid 56 achieve sustained virologic 56 potentiation 56 biochemical relapse 56 symptomatic paroxysmal AF 56 DOXIL 56 peginterferon 56 inducible nitric oxide synthase 56 favorable pharmacokinetic profile 56 coinfected patients 56 glycosylated hemoglobin HbA1c 56 coadministration 56 IFN gamma 56 p = NS 56 ZOLINZA 56 genotypic resistance 56 circulating EPCs 56 PegIFN RBV 56 clinicopathological features 56 neutrophil counts 56 recurrent glioblastoma 56 leukemic transformation 56 COPD exacerbation 56 intracranial hemorrhage ICH 56 pretransplant 56 leukemia CLL 56 candidemia 56 hepatotoxicity 56 colorectal liver metastases 56 ponatinib 56 CPAP adherence 56 CD8 T cell 56 Prognostic factors 56 arteriography 56 paroxysmal AF 56 hepatocellular carcinomas 56 nodal metastases 56 glycemia 56 antiresorptive 56 TNF inhibitor 56 rindopepimut 56 methotrexate therapy 56 knee osteoarthritis OA 56 histologies 56 corrected QT interval 56 standard chemotherapy regimen 56 sustained virological response 56 biochemical marker 56 neutropenic patients 56 cediranib 56 CD# expression [002] 56 KRAS status 56 virologic breakthrough 56 antiangiogenic agent 56 HNSCC 56 neutropaenia 56 PITX2 56 PARP inhibition 56 lung metastasis 56 SSc 56 stratifying patients 56 serum HBV DNA 56 antidepressant efficacy 56 doxorubicin docetaxel 56 leucopenia 56 variant allele 56 immunological responses 56 CIN2 + 56 neoadjuvant treatment 56 dysfunction LVSD 56 gastric adenocarcinoma 56 ICD shocks 56 gemcitabine Gemzar ® 56 micrometastasis 56 imatinib resistant 56 Barrett esophagus BE 56 estramustine 56 humoral responses 56 thyroglobulin 56 postdose 56 mitochondrial toxicity 56 BEACOPP 56 pharmacologic intervention 56 anti leukemic 56 telomerase inhibition 56 elacytarabine 56 GAMMAGARD 56 CD4 lymphocyte count 56 esophageal candidiasis 56 therapeutic regimens 56 HbF 56 eosinophilic asthma 56 radical prostatectomy RP 56 carbonic anhydrase inhibitors 56 postoperative radiotherapy 56 superficial bladder cancer 56 airway responsiveness 56 myeloproliferative diseases 56 SLNB 56 serum testosterone 56 hyperprolactinemia 56 hormone deprivation 56 Helicobacter infection 56 CIMZIA TM 56 erythropoietic 56 poststroke depression 56 univariate analyzes 56 hippocampal atrophy 56 solifenacin 56 Vojo Vukovic MD Ph.D. 56 thalidomide dexamethasone 56 comorbid disorders 56 gemcitabine Gemzar 56 CD# upregulation 56 pheochromocytoma 56 nephrotoxic 56 randomized multicenter Phase III 56 Multivariate analysis 56 multiple myeloma MM 56 clinically meaningful improvements 56 hypotensive 56 prostate carcinoma 56 Virulizin ® 56 SPRYCEL ® 56 GnRH agonist 56 nonalcoholic steatohepatitis NASH 56 nephrotoxic drugs 56 seroprotection 56 vasopressor 56 pathologic fractures 56 postprandial insulin 56 lactic acidosis 56 HBsAg 56 chest radiography 56 standard chemotherapy regimens 56 macroalbuminuria 56 Helicobacter pylori eradication 56 EGFR mutations 56 cytogenetic responses 56 intravascular hemolysis 56 Randomized clinical trials 55 Immunohistochemical analysis 55 unfavorable cytogenetics 55 pretargeting 55 protein excretion 55 TORISEL 55 antiarrhythmic 55 malignant transformation 55 gastric carcinoma 55 allogeneic SCT 55 eplerenone 55 mucinous 55 HepG2 cells 55 hemodilution 55 postprocedure 55 platelet activation 55 carotid stenosis 55 cardioprotective effects 55 certolizumab 55 hematological toxicity 55 STRIDE PD 55 demonstrated antitumor activity 55 pharmacokinetic interactions 55 cardiac troponin 55 rhGH 55 poor metabolizers 55 BMPR2 55 repolarization 55 endometrial adenocarcinoma 55 hour bronchodilation 55 NYHA functional class 55 isoenzyme 55 ADPKD 55 pressure natriuresis 55 serum PSA 55 renoprotective 55 non metastatic osteosarcoma 55 4mg/kg 55 Cimzia TM 55 subclinical hypothyroidism 55 nitazoxanide 55 pre malignant lesions 55 CEACAM1 55 HCV replicon 55 postoperative morbidity 55 TT genotype 55 adjuvant radiotherapy 55 tracer uptake 55 molecular determinants 55 prognostic indicator 55 spontaneous bacterial peritonitis 55 pain palliation 55 empiric treatment 55 carcinoembryonic antigen 55 indolent NHL 55 low dose dexamethasone 55 IL 1β 55 acute mania 55 neointimal 55 samalizumab 55 FOLPI 55 neurologic progression 55 eculizumab therapy 55 Akt activation 55 dosing cohort 55 lesional 55 apremilast 55 elevated transaminases 55 ventricular dysfunction 55 preoperative chemotherapy 55 microtubule targeting 55 PSADT 55 ERK activation 55 aminotransferase 55 pharmacodynamic effects 55 transaminases 55 HOMA IR 55 FDG uptake 55 paclitaxel eluting stents 55 nilotinib 55 alefacept 55 XELOX 55 anemia neutropenia 55 HGS ETR2 55 cytotoxic chemotherapy 55 chemoradiation 55 RRMS patients 55 divalproex sodium 55 premalignant lesions 55 recurrent myocardial infarction 55 rituximab Rituxan ® 55 serum concentrations 55 baseline LDH 55 HIV coinfected 55 T2DM 55 BRAF inhibitors 55 serologic 55 dose proportionality 55 endothelial activation 55 esophageal carcinoma 55 differentiated thyroid 55 UGT#A# * 55 BCR ABL mutation 55 radical cystectomy 55 immunoreactivity 55 Secondary endpoints 55 vidofludimus 55 myocardial dysfunction 55 MCyR 55 androgen suppression therapy 55 noninfectious uveitis 55 TPMT 55 INVEGA ® 55 autoantibody levels 55 proliferative disorders 55 VKORC1 55 nab paclitaxel 55 adverse cytogenetics 55 tolterodine 55 serum PTH 55 remission CR 55 concurrent chemoradiation 55 Insulin PH# 55 KRAS mutations 55 Flu Cy 55 perfusion abnormalities 55 TOP2A 55 affective psychosis 55 brivaracetam 55 cytoprotective 55 Brugada syndrome 55 NATRECOR R 55 relapsed ALL 55 proinflammatory cytokine 55 insulin detemir 55 moderate renal impairment 55 independent prognostic marker 55 reinfarction 55 prospectively defined 55 urate lowering 55 APOE e4 55 TNF blocker therapy 55 effector function 55 neuroleptic 55 angiotensin converting enzyme inhibitor 55 metastatic lung cancer 55 forodesine 55 status epilepticus 55 clinically meaningful reductions 55 receiving VICTRELIS 55 gemcitabine carboplatin 55 anthracycline therapy 55 QTcF 55 serum aminotransferase levels 55 androgen independent 55 Suicidal ideation 55 renal cell carcinomas 55 Randomized trials 55 immunomodulatory therapy 55 IGF 1R inhibitor 55 androgen receptor pathway 55 LTBI 55 thromboembolic 55 nutlin 3a 55 glucose intolerant 55 OHR/AVR# 55 eosinophilia 55 bullous pemphigoid 55 humoral immune response 55 dose dexamethasone 55 mg/m2 cohort 55 Apoptone 55 comorbid psychiatric 55 thromboembolic events 55 TURBT 55 flavopiridol 55 Crohn Disease Activity 55 adjuvant therapies 55 growth hormone secretion 55 #F FDG PET 55 antiarrhythmic drug 55 postoperative hemorrhage 55 methacholine challenge 55 GABRA2 55 genetic polymorphisms 55 STAT3 signaling 55 chronic HBV infection 55 PTPN# 55 pegylated liposomal doxorubicin 55 pancreatic carcinoma 55 metabolic parameters 55 CD8 cell 55 prostate cancer PCa 55 ancrod 55 serous ovarian cancer 55 antimetabolite 55 cerebrovascular events 55 liver histology 55 CD#c 55 NIHSS score 55 autonomic dysfunction 55 mediated inhibition 55 T#I [002] 55 serum phosphorous 55 myeloproliferative disorder 55 Ceplene/IL-2 55 coinfection 55 atrial tachyarrhythmias 55 antiangiogenic agents 55 transurethral resection 55 bicalutamide 55 GLP 1R 55 weekly subcutaneous injections 55 mg/m2 dose 55 AGILECT R 55 HLA alleles 55 relapsed SCLC 55 glial tumors 55 chromosomal aberrations 55 ERK1 2 55 silent myocardial ischemia 55 liver biopsies 55 trabedersen 55 pharmacodynamic markers 55 plasminogen activators 55 metastatic RCC 55 cisplatin resistant 55 GnRH agonists 55 locoregional 55 microvessel density 55 hemorrhagic complications 55 heterozygotes 55 SUVmax 55 acid suppressive therapy 55 HCD# [002] 55 rechallenge 55 biologic plausibility 55 EGFR TKI 55 CVD mortality 54 RRM1 54 CANCIDAS 54 immunosuppressive regimen 54 prognostic markers 54 neratinib 54 binary restenosis 54 intravenous tPA 54 axitinib 54 percutaneous biopsy 54 genomic alterations 54 achieved CCyR 54 TMEM density 54 adalimumab Humira 54 chemopreventive agent 54 cerebral ischemia 54 GRN# 54 GvHD 54 serum bicarbonate 54 ritonavir boosted 54 neuropsychiatric symptoms 54 pathophysiological mechanisms 54 CTEPH 54 serum clusterin levels 54 vaso occlusive crisis 54 atherothrombotic 54 bexarotene 54 metastatic lesions 54 ischemic lesions 54 potent neuroprotective 54 Hp2 2 54 follicular lymphomas 54 diabetes mellitus DM 54 HbA 1c levels 54 EGFR tyrosine kinase inhibitor 54 ABCB1 54 conditional logistic regression 54 statistically significant efficacy 54 ischemia induced 54 ximelagatran 54 overt nephropathy 54 antithrombotic 54 sitaxsentan 54 pituitary hormone 54 microbiological eradication 54 MICARDIS ® 54 detrusor overactivity 54 chronic periodontitis 54 GRNCM1 54 baseline HbA1c 54 severe hypersensitivity reactions 54 PNH patients 54 ATACAND 54 hypomanic episodes 54 malignant lymphomas 54 prostate epithelial cells 54 colorectal cancer liver metastases 54 cytoreduction 54 urolithiasis 54 DAPT 54 FOLFOX4 54 refractory Hodgkin 54 TMPRSS2 ERG fusion 54 hepatitis C genotype 54 murine models 54 DLTs 54 osteogenic 54 chlamydial 54 Kaplan Meier analysis 54 Lymph node 54 anti Xa 54 Bcr Abl mutations 54 severe exacerbations 54 SSRI SNRI 54 rhEPO 54 alpha#beta# integrin 54 antirheumatic 54 non squamous histology 54 interferon IFN 54 experimentally induced 54 imipenem 54 CINTREDEKIN BESUDOTOX 54 liver transaminases 54 lymphopenia 54 immune thrombocytopenic purpura ITP 54 clinically insignificant 54 nicardipine 54 levodopa carbidopa 54 neutropenic fever 54 p = .# [002] 54 immune modulating 54 anti HBs 54 angiotensin converting enzyme inhibitors 54 Xanafide 54 ribavirin RBV 54 thetreatment 54 sarcomatoid 54 iroxanadine 54 Solid Tumors criteria 54 Cinquil 54 maximal doses 54 rituximab 54 Fludara 54 neuropsychological impairments 54 recurrent genital herpes 54 response pCR 54 pharmacodynamics PD 54 cardiotoxic 54 FOLFIRI 54 HBeAg negative 54 antiandrogen 54 serum estradiol 54 pharmacodynamic parameters 54 systemic toxicity 54 IL#B 54 neurologic complications 54 primary aldosteronism 54 decompensated cirrhosis 54 haematological toxicity 54 infliximab 54 cytoreductive nephrectomy 54 clusterin 54 neurocognitive outcomes 54 corticosteroid dose 54 evaluable subjects 54 liver metastases 54 postoperative mortality 54 serum potassium 54 TDF FTC 54 d dimer 54 rhIGFBP 3 54 platinum refractory 54 promoter methylation 54 blood glucose concentrations 54 oxygen desaturation 54 KRAS mutation status 54 vandetanib 54 neurologic symptoms 54 serologic tests 54 cardiac valvulopathy 54 anthracyclines taxanes 54 intracellular bacteria 54 chemoresistant 54 velafermin 54 incidence ≥ 54 apneic episodes 54 primary hyperparathyroidism 54 CDAI 54 FDG PET scans 54 residual platelet reactivity 54 inotropic 54 fetuin 54 ADAGIO study 54 unruptured aneurysm 54 intravesical 54 HCV infection 54 pulmonary exacerbations 54 serum phosphate 54 urothelial carcinoma 54 Pemetrexed 54 #q# deletion syndrome 54 gastrointestinal stromal tumors GIST 54 dasatinib Sprycel 54 dobutamine 54 hyperinsulinemia 54 tryptase 54 homozygotes 54 atherogenic dyslipidemia 54 QTc interval 54 virologic suppression 54 VELCADE melphalan 54 ventricular tachyarrhythmia 54 demyelinating 54 cortical stimulation 54 small lymphocytic lymphoma 54 detectable HCV RNA 54 neuroinflammatory 54 schizophrenia CIAS 54 CD# expression [001] 54 fluoroquinolone resistance 54 salmeterol fluticasone 54 intrahepatic 54 β blocker 54 nodular partial response 54 CYP #A# 54 plasma triglycerides 54 pathologic 54 ERBB2 54 baroreceptor 54 liver resection 54 renal allograft 54 cellularity 54 cytopenia 54 amrubicin 54 synovial cells 54 locomotor activity 54 INFERGEN 54 Aptivus ® 54 microsatellite instability 54 vasodilatation 54 TLE3 54 da mage 54 polycythemia vera PV 54 glioblastoma tumors 54 IOP lowering 54 receiving highly emetogenic 54 plasma viremia 54 Solorel TM 54 Sjögren syndrome 54 plasma glucose 54 intestinal permeability 54 hepatic cirrhosis 54 cytogenetic response 54 bronchoalveolar lavage fluid 54 radiosensitivity 54 sorafenib Nexavar 54 ICD therapy 54 Paliperidone 54 gene amplification 54 FAMPYRA 54 HIV seroconversion 54 TNFa 54 dose escalation phase 54 HBV DNA levels 54 median survivals 54 serum uric acid 54 HBeAg negative patients 54 APOE genotype 54 serum homocysteine 54 hypomagnesemia 54 SNP rs# [002] 54 mutated K ras 54 CA4P 54 pleurodesis 54 TNF inhibitors 54 TriGrid ™ 54 clodronate 54 selective modulator 54 allergic airway inflammation 54 hepatic metastases 54 octreotide 54 SCr 54 Jevtana 54 radiotherapy RT 54 hemodynamic responses 54 rs# [002] 54 extrapyramidal symptoms 54 neuronal dysfunction 54 antiretroviral naive 54 telomere lengths 54 cytokine interleukin 54 ERCC1 54 penetrance 54 colorectal adenocarcinoma 54 prognostic marker 54 RSD# 54 scintigraphic 54 somatostatin analogues 54 MMSE score 54 heavily pretreated patients 54 MGUS 54 concomitant AEDs 54 Hematologic toxicity 54 deferiprone 54 sargramostim